·More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1 ·DRD is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe.2,3 ·There is an urgent need for earlier detection of DRD [...]
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare services for all, with a special focus on vulnerable populations in the Americas who are at greater risk of suicide. Through this partnership with the WHO Foundation, [...]
Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable suffering, stigma, disability, and death caused by non-communicable diseases (NCDs). The start of the partnership was announced alongside the United Nations Global Assembly in [...]
Inauguration of Angelika Amon research building in Vienna Sustainable research building at a cost of EUR 60 million offers modern office and laboratory space Over the past five years, Boehringer’s capital investments reached EUR 6.0 billion Boehringer Ingelheim is one of the world’s leading research-oriented pharmaceutical companies. The clinical pipeline is constantly being further developed, [...]
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 versus placebo. The FIBRONEER™-IPF trial is the largest trial in idiopathic pulmonary fibrosis (IPF) conducted to date. Patients were recruited in over 330 sites and in [...]
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1 Preliminary activity in patients with brain metastases were also observed, with an intracranial response of 33% and 74% disease control rate (DCR) Zongertinib was generally well tolerated, with mostly mild [...]
Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record | ClinicalTrials.gov), an investigational antibody fragment developed to preserve vision in people living with geographic atrophy (GA). BI 771716 met its primary safety endpoint following intravitreal administration of single and multiple [...]
INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic diseases in pets. With the acquisition, Boehringer Ingelheim strengthens its animal health research and development (R&D) pipeline, specifically in the fast-growing pet therapeutics category. As life [...]
Data from the phase Ib Beamion LUNG-1 trial selected for late-breaking oral presentation in the Presidential Symposium at WCLC on Monday, September 9. The U.S. FDA and China’s CDE have granted zongertinib Breakthrough Therapy Designation for patients with HER2-mutated NSCLC and who have received prior systemic therapy. Phase I trial data of a novel DLL3-targeting [...]
The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction of the risk of GPP flares was observed. GPP is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin flares and systemic [...]